ERAS
Erasca, Inc.
A clinical-stage biopharmaceutical company developing medicines for cancers driven by the RAS/MAPK pathway, one of the most frequently mutated signaling routes in human tumors. Founded in San Diego in 2018, its name blends "RAS" with "era," reflecting a mission to open a new era in treating RAS-driven cancers. The company is building a pipeline of experimental drugs aimed at this stubborn family of cancer-causing proteins.
CUSIP: 29479A108HealthcareUS1 holder
Total Value
$3.86M
Total Shares
210.9K
Net Share Change
+131.9K
Activity
1 buying
Investor
Value
Shares
Weight
Change
